Pulmonary arterial hypertension (PAH) is an orphan condition with high morbidity and mortality. Despite increased awareness of pulmonary hypertension (PH), data indicate that the majority of patients are still diagnosed in late stages of the disease. A higher World Health Organization functional class is associated with poorer median survival, illustrating the importance of early diagnosis. In this article, we were asked to defend the value of noninvasive imaging in the diagnosis and follow-up of PH. Although we agree that at this point, invasive assessment remains essential, in the long term it is hoped that noninvasive methods will eliminate the need for invasive assessment. Our original mandate was to discuss PAH; however, because this is a rare condition with relatively little information available, we have broadened our approach to include PH in general.

Limitations of Invasive Assessment {#sec1}
==================================

Invasive hemodynamic assessment by right heart catheterization is relatively safe but has technical limitations {#sec1.1}
---------------------------------------------------------------------------------------------------------------

At the Nice 5th World Symposium on PH, right heart catheterization (RHC) was confirmed as essential for the diagnostic workup of PH to assess the severity of the disease and to perform a vasoreactivity test.[@bib1; @bib2; @bib3] However, RHC is associated with rare, albeit serious, procedure-related complications, including death. In an analysis of 7218 RHC procedures performed in experienced PH centres, 76 serious adverse events, including 4 fatalities, were observed. The most common serious adverse events were supraventricular and ventricular tachycardia, vagal reactions, and systemic hypotension.[@bib4] Although RHC is relatively safe, reports of complications do appear, even in expert centres.[@bib5]

Data acquisition during RHC requires resting supine patients. There is no standard operating procedure for capturing hemodynamic changes that occur with an upright posture or with physical activity using RHC. In addition, hemodynamic measurements acquired by RHC are subject to intraindividual spontaneous variability and represent only a hemodynamic snapshot.[@bib1; @bib6]

Routine RHC relies on the use of fluid-filled catheters, which have an insufficient frequency response.[@bib7] Standard Swan-Ganz catheter manometry systems used in clinical practice have a frequency response of 12 Hz, whereas a minimum of 50 Hz would be required for the assessment of instantaneous pressure signals.[@bib7] Fluid-filled catheters require fast flushes to remove air bubbles in the monitoring system, which account for most of the variability compared with the true gold-standard high-fidelity micromanometer-tipped catheters.[@bib7] In contrast to high-fidelity micromanometer-tipped catheter systems, fluid-filled catheter transducers have to be positioned at a "zero reference level," which is most accurately obtained at midthoracic level or at one third of the thoracic diameter below the anterior thorax surface.[@bib8] A deviation of 1 cm of the transducer from zero level affects pressures by 0.78 mm Hg, thus leading to significantly different results if 2 different zero reference levels are used in a single patient.[@bib8]

Currently used invasive cardiac output measurements estimate but do not measure true cardiac output {#sec1.2}
---------------------------------------------------------------------------------------------------

The gold standard for the assessment of cardiac output (CO) is the direct Fick method in which CO equals O~2~ consumption divided by the difference between arterial and venous O~2~ content. Although O~2~ consumption can be measured accurately, that measurement is cumbersome, and many laboratories use standard tables for an assumed value instead of direct measurements. Such estimation may cause an error of as much as 40% in the assessment of CO.[@bib9] Most laboratories now use thermodilution based on an indicator dilution methodology to measure CO.[@bib10] When compared with the direct Fick method, thermodilution measurements show little bias, with a mean difference of 0.1 L/min and a confidence interval of 0.2 L/min, corresponding to excellent accuracy even in the presence of tricuspid regurgitation, but limits of agreement are ± 1 L/min, corresponding to moderate precision.[@bib11]

Need for an integrated diagnostic approach {#sec1.3}
------------------------------------------

Clinically significant information is gained from RHC that helps guide decisions. A restrictive use of RHC may delay a timely diagnosis and treatment.[@bib6] Still, the simple distinction between pre- and postcapillary PH is a task that often cannot even be achieved by invasive RHC. In particular, heart failure with preserved ejection fraction is commonly misdiagnosed as precapillary PH.[@bib12; @bib13; @bib14] Unresolved issues are the assessment of precatheterization fluid status, standardization of fluid loading,[@bib3; @bib15; @bib16] and mean pulmonary arterial wedge pressure measurements---end-expiratory or as pressure-time integral.[@bib16; @bib17] The interpretation of invasive hemodynamics is meaningless outside the context of the clinical picture, in particular echocardiography.[@bib1; @bib3] To manage the growing number of PH cases resulting from left heart disease (group 2 PH) and caused by lung disease/hypoxia (group 3 PH) in the general population, successful noninvasive diagnostic algorithms combining multiple parameters have been developed to avoid unnecessary RHC.[@bib1; @bib18]

Present Value of Noninvasive Techniques {#sec2}
=======================================

Advanced imaging tools are useful for screening {#sec2.1}
-----------------------------------------------

Transthoracic Doppler echocardiography is the predominant screening modality in early stages of diagnosis to assess right ventricular (RV) structure and function, including the degree of ventricular remodelling as well as the derivation of RV systolic and diastolic pressures and analysis of contraction timing,[@bib19; @bib20; @bib21; @bib22; @bib23] thus providing a reliable method for the early detection of PH, with a particularly high sensitivity and specificity in systemic sclerosis ([Table 1](#tbl1){ref-type="table"}). Recently, software programs for 2-dimensional (2D) strain analysis by speckle tracking have been applied to evaluate the right ventricle.[@bib31] Furthermore, significant progress has been made in the use of knowledge-based reconstruction of 3D RV structure and function from 2D images.[@bib32] Studies have suggested that 3D echocardiographic imaging of the right ventricle is feasible, and its results compare well with magnetic resonance imaging (MRI).[@bib33; @bib34]

Theoretically, imaging of the pulmonary vasculature should be more sensitive to screening because this is where disease starts; yet, the available methods do not appear to have reached adequate sensitivity and specificity for that purpose.[@bib35]

Advanced imaging tools are useful for diagnosis {#sec2.2}
-----------------------------------------------

Any patient with unexplained PH should be evaluated for chronic thromboembolic PH (CTEPH). Diagnostic algorithms for PH include ventilation/perfusion (V/Q) scintigraphy,[@bib1; @bib36; @bib37; @bib38; @bib39; @bib40] multidetector computed tomography (CT), and cardiac MRI (cMRI).[@bib41] Although a mosaic pattern is common in CTEPH, it occurs in up to 12% of patients with PAH.[@bib42] MRI of the pulmonary vasculature is still considered inferior to CT but may be preferred according to local practice.[@bib43] Recent advances---such as dual-energy CT,[@bib44] cone-beam CT, electrocardiographic gated 320-row area detector CT, and lung perfusion MRI---are about to change paradigms in pulmonary vascular imaging. In a pilot study, dynamic contrast-enhanced CT was used to distinguish between patients with and those without PAH by contrast material bolus propagation time and speed in the pulmonary arteries.[@bib45] Time differences between bolus peaks correlated with mean pulmonary artery pressures, and discrimination could be achieved with a sensitivity of 100% and specificity of 100% in patients without PH and a sensitivity of 93% and specificity of 80% in patients with PAH, respectively ([Table 2](#tbl2){ref-type="table"}).[@bib45]

Suspicion should be high when the patient presents with a history of previous venous thromboembolism (VTE). Although formal screening cannot be recommended, CTEPH should be ruled out in any survivor of a pulmonary embolism with persistent dyspnea and \> 15% perfusion defects 6 months after the acute VTE after at least 3 months of effective oral anticoagulation.[@bib40] V/Q planar images in at least 6 views combined with single-photon emission CT remains the preferred initial diagnostic test for CTEPH. CT pulmonary angiography (CTPA) has a sensitivity of detecting CTEPH of 51%, compared with a \> 96% sensitivity of V/Q scanning.[@bib62] A normal V/Q, but not a normal CTPA, can exclude CTEPH, although scans tend to normalize as disease progresses.[@bib63] CTEPH may be the single PH subset in which advanced imaging and not RHC may be the primary approach to diagnosis, follow-up, and management. In the example shown in [Figure 1](#fig1){ref-type="fig"}, the correct diagnosis of CTEPH was made after an echocardiogram and a V/Q scan had been obtained. A CTEPH diagnosis was later confirmed by RHC and pulmonary angiography.

Advanced imaging tools are useful for follow-up and management {#sec2.3}
--------------------------------------------------------------

An important more recent finding is that although PH is a pulmonary vascular disorder, structural and functional assessments of the right ventricle play a central role in both diagnosis and serial follow-up of patients with PAH.[@bib23] Therefore, it is reasonable that current guidelines suggest an integrated diagnostic algorithm in which noninvasive modalities are targeted to RV function and can be serially assessed to detect changes ([Table 3](#tbl3){ref-type="table"}); such an algorithm will play an ever more important role in the near future.[@bib1] For example, the use of 3D speckle tracking to assess area strain, radial strain, longitudinal strain, and circumferential strain correlates with clinical outcomes, with area strain and circumferential strain correlating best with RV ejection fraction.[@bib70] Stroke volume and RV ejection fraction measured by cMRI are the most commonly used parameters to evaluate global systolic RV function and to assess response to therapy.[@bib74; @bib75; @bib79] However, these parameters are highly dependent on preload and afterload and do not reflect RV contractility.[@bib80] RV end-systolic elastance (Ees) is accepted as a load-independent measure of intrinsic myocardial contractility. E~es~ is usually derived from pressure-volume loops by invasive conductance catheterization. Using this method, arterial elastance (E~a~) as a measure of RV afterload can also be determined. RV-to--pulmonary vascular (RV-PV) coupling, the adaptation of the right ventricle to its afterload, can be calculated by E~es~ divided by E~a~ (E~es~/E~a~ ratio). However, this method requires the assessment of pressure-volume loops during preload reduction by temporary balloon occlusion of the inferior vena cava, thus making it very invasive and potentially dangerous. As an alternative, E~es~/E~a~ can also be determined by combining measurements from standard RHC and MRI. Studies in healthy individuals and patients with PH have shown good agreement of MRI conductance catheterization data.[@bib81; @bib82] The ratio of stroke volume--to--end-systolic volume (SV/ESV) that can be derived completely noninvasively from cMRI was found to correlate well with RV-PV coupling and to be a strong predictor of prognosis.[@bib78]

Conclusions {#sec3}
===========

Because of the intrinsic properties of invasive diagnostics, the desire of patients, patient advocates, and physicians is that advanced imaging tools rather than hemodynamics will eventually become the primary approach to diagnosing, following, and managing PH. The values of sensitivities and specificities of available methods shown in [Tables 1-3](#tbl1 tbl2 tbl3){ref-type="table"} allow for the selection of the best noninvasive tests for screening, diagnosis, and follow-up in PH, according to testing priorities. Although noninvasive assessment cannot currently replace RHC, it has become an essential part of the management paradigm for PH, and hopefully with further development will 1 day make RHC a historical curiosity.
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![Imaging in a 24-year-old woman with a history of progressive shortness of breath on exertion, deep vein thrombosis, and recent hemoptysis. (**A**) Transthoracic echocardiographic 4-chamber view with severe right ventricular dilatation. (**B**) Technetium-99m--labeled aerosol ventilation and (**C**) perfusion images show nonmatched perfusion defects of right lower lobe and almost the entire left lung.](gr1){#fig1}

###### 

Noninvasive imaging to screen for PH

  First author                  Technique   Number of patients   Study population/cause   Functional parameter/variable          Screening for PH   
  ----------------------------- ----------- -------------------- ------------------------ -------------------------------------- ------------------ ------
  Denton et al.[@bib24]         TTE         33                   CTD (SSc)                sPAP                                   90                 75
  Parent et al.[@bib25]         TTE         385                  Sickle cell disease      Tricuspid regurgitation jet velocity   100                80
  Rajaram et al.[@bib26]        TTE         81                   CTD                      Tricuspid gradient                     86                 82
  Wang et al.[@bib27]           TTE         123                  CHD                      sPAP                                   89                 84
  Kuriyama et al.[@bib28]       CT          23                   Suspected PH             MPAD                                   69                 100
  Perez-Enguix et al.[@bib29]   CT          71                   Candidates for LTX       MPAD                                   66                 86
  Rajaram et al.[@bib26]        CT          81                   CTD                      Ventricular mass index                 85                 82
  Stevens et al.[@bib30]        MRI         100                  Suspected PH             PVR                                    92.5               85.2
  Rajaram et al.[@bib26]        MRI         81                   CTD                      RV mass index                          85                 82

CHD, congenital heart disease; CT, computed tomography; CTD, connective tissue disease; LTX, lung transplantation; MPAD, main pulmonary artery diameter; MRI, magnetic resonance imaging; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RV, right ventricular; sPAP, systolic pulmonary artery pressure; SSc, systemic sclerosis/scleroderma; TTE, transthoracic echocardiography.

###### 

Noninvasive imaging to diagnose PH

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author                Technique   No. of patients   Study population/cause     Functional parameter/variable       Diagnosing PAH                              
  --------------------------- ----------- ----------------- -------------------------- ----------------------------------- ------------------------------------------- -------------------------------------------
  Isobe et al.[@bib46]        TTE         77                Controls vs suspected PH   RV acceleration time                93                                          97

  Tei et al.[@bib47]          TTE         63                Controls vs iPAH           Tei index                           --                                          --

  Saba et al.[@bib48]         TTE         26                Suspected PH               sPAP                                89                                          57

  Hsu et al.[@bib49]          TTE         49                CTD (SSc)                  sPAP                                58                                          96

  Dahiya et al.[@bib50]       TTE         26                Suspected PH               Corrected PVR\                      91\                                         90\
                                                                                       Echocardiographic PVR               93                                          91

  D\'Alto et al.[@bib51]      TTE         161               Suspected PH               Left atrial pressure\               85\                                         --\
                                                                                       Cardiac output\                     --\                                         --\
                                                                                       mPAP\                               --\                                         --\
                                                                                       PVR                                 --                                          --

  Gladue et al.[@bib52]       TTE         248               CTD (SSc)                  sPAP                                94[∗](#tbl2fnlowast){ref-type="table-fn"}   73[∗](#tbl2fnlowast){ref-type="table-fn"}

  Tan et al.[@bib53]          CT          45                Suspected PH               MPAD                                87                                          89

  Chan et al.[@bib54]         CT          101               Suspected PH               MPAD\                               77\                                         90\
                                                                                       MPAD/AA ratio\                      74\                                         92\
                                                                                       MPAD/DA ratio\                      77\                                         90\
                                                                                       Right descending PA diameter\       83\                                         85\
                                                                                       RV/LV lumen ratio\                  86\                                         86\
                                                                                       RV/LV wall ratio\                   79\                                         84\
                                                                                       RV free wall\                       81\                                         92\
                                                                                       True left descending PA diameter\   79\                                         92\
                                                                                       True right descending PA diameter   83                                          88

  Corson et al.[@bib55]       CT          305               Suspected PH               Right PA diameter\                  89 (85-94)\                                 82 (74-89)\
                                                                                       MPAD                                89 (84-93)                                  83 (76-90)

  Helmberger et al.[@bib56]   CT          24                Controls vs PH             Pulmonary vessel tortuosity         83                                          83

  Pienn et al.[@bib45]        CT          21                Controls vs PAH            Propagation contrast medium speed   100 (77-100)                                100 (48-100)

  Bouchard et al.[@bib57]     MRI         27                Controls vs PAH            Left descending PA/DA\              --                                          --
                                                                                       MPAD\                                                                           
                                                                                       MPAD/AA\                                                                        
                                                                                       RV wall thickness\                                                              
                                                                                       Septal wall thickness                                                           

  Saba et al.[@bib48]         MRI         26                Suspected PH               Ventricular mass index              84                                          71

  Sanz et al.[@bib58]         MRI         59                Controls vs PAH            Average blood velocity\             93 (81-98)\                                 82 (57-96)\
                                                                                       Minimum PA area                     93 (81-98)                                  88 (64-98)

  Sanz et al.[@bib58]         MRI         72                PH                         Delayed contrast enhancement        --                                          --

  Hsu et al.[@bib49]          MRI         49                CTD (SSc)                  MPAD                                68                                          71

  Nogami et al.[@bib59]       MRI         20                Suspected PH               sPAP\                               --\                                         --\
                                                                                       Stroke volume                       --                                          --

  Shehata et al.[@bib60]      MRI         48                Controls vs PAH            RV longitudinal strain\             --\                                         --\
                                                                                       RV circumferential strain\          --\                                         --\
                                                                                       RV tangential strain                --                                          --

  Swift et al.[@bib61]        MRI         64                Suspected PH               sPAP\                               87                                          90
                                                                                       PVR                                                                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AA, ascending aorta; CT, computed tomography; DA, descending aorta; CTD, connective tissue disease; iPAH, idiopathic pulmonary arterial hypertension; LV, left ventricular; MPAD, main PA diameter; mPAP, mean PA pressure; MRI, magnetic resonance imaging; PA, pulmonary artery; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RV, right ventricular; sPAP, systolic PA pressure; SSc, systemic sclerosis/scleroderma; TTE, transthoracic echocardiography.

In combination with pulmonary function tests.

###### 

Noninvasive imaging to follow-up/detect change in PH

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author                     Technique   No. of patients   Study population/cause               Functional parameter/variable          Detecting change in PAH/CTEPH/PH   
  -------------------------------- ----------- ----------------- ------------------------------------ -------------------------------------- ---------------------------------- ------------
  Chow et al.[@bib64]              TTE         28                Operable CTEPH before vs after PEA   Acceleration time\                     --\                                --\
                                                                                                      Tricuspid regurgitation jet velocity   --                                 --

  Eysmann et al.[@bib65]           TTE         26                iPAH                                 Pericardial effusion\                  --\                                --\
                                                                                                      Tricuspid early flow deceleration\     --\                                --\
                                                                                                      Pulmonary acceleration time            --                                 --

  Tei et al.[@bib47]               TTE         63                Controls vs iPAH                     Tei index                              --                                 --

  Yeo et al.[@bib66]               TTE         53                iPAH                                 Tei index                              --                                 --

  Raymond et al.[@bib19]           TTE         81                iPAH                                 Right atrial area index\               --\                                --\
                                                                                                      Diastolic eccentricity index\          --\                                --\
                                                                                                      Pericardial effusion                   --                                 --

  Forfia et al.[@bib67]            TTE         63                PAH                                  TAPSE                                  --                                 --

  Dahiya et al.[@bib50]            TTE         10                PAH                                  Corrected PVR\                         --\                                --\
                                                                                                      Echocardiographic PVR                  --                                 --

  Fine et al.[@bib68]              TTE         575               PH                                   RV longitudinal strain\                79\                                --\
                                                                                                      TAPSE                                  61                                 --

  Grünig et al.[@bib69]            TTE         124               PAH/CTEPH                            sPAP; response to exercise             77                                 53

  Smith et al.[@bib70]             TTE         97                PH                                   RV ejection fraction\                  65\                                59\
                                                                                                      TAPSE\                                 70\                                59\
                                                                                                      RV area strain\                        80\                                54\
                                                                                                      RV circumferential strain\             65\                                73\
                                                                                                      RV longitudinal strain\                90\                                52\
                                                                                                      RV radial strain                       75                                 51

  Courand et al.[@bib71]           TTE         100               PAH                                  RV ejection fraction                   --                                 --

  Moledina et al.[@bib35]          CT          31                Pediatric PAH                        Fractal dimension                      --                                 --

  Zylkowska et al.[@bib72]         CT          264               PAH/CTEPH                            MPAD                                   95                                 39

  van Wolferen et al.[@bib73]      MRI         64                PAH                                  RV ejection fraction\                  --\                                --\
                                                                                                      RV end-diastolic volume index\         --\                                --\
                                                                                                      LV end-diastolic volume index\         --\                                --\
                                                                                                      Stroke volume index                    --                                 --

  van de Veerdonk et al.[@bib74]   MRI         76                PAH                                  RV ejection fraction                   82                                 75

  Freed et al.[@bib75]             MRI         58                PH                                   RV ejection fraction\                  100                                --
                                                                                                      RVIP-LGE                                                                  

  Ley et al.[@bib76]               MRI         20                PAH/CTEPH                            Cardiac output                         --                                 --

  Pandya et al.[@bib77]            MRI         50                Pediatric PAH (CHD)                  Septal curvature                       83 (36-99)                         91 (77-97)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CT, computed tomography; CHD, congenital heart disease; CTEPH, chronic thromboembolic pulmonary hypertension; iPAH, idiopathic pulmonary arterial hypertension; LGE, late gadolinium enhancement; LV, left ventricular; MPAD, mean PA diameter; MRI, magnetic resonance imaging; PA, pulmonary artery; PAH, pulmonary arterial hypertension; PEA, pulmonary thromboendarterectomy; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RV, right ventricular; RVIP, RV insertion point; sPAP, systolic PA pressure; SV/ESV, stroke volume/end-systolic volume ratio; TAPSE, tricuspid annular plane excursion; TTE, transthoracic Doppler echocardiography.
